Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection

Ghasemi, Ali; Jeddi-Tehrani, Mahmood; Mautner, Josef; Salari, Mohammad; Zarnani, Amir‐Hassan

doi:10.1016/j.vaccine.2015.09.013

Cited by 39 publications

(15 citation statements)

References 49 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further multivalent subunit vaccine formulations possess the capability to generate a wide range of immunogens that may result in better protection than their univalent counterpart [24][25][26]. In this study, we evaluated humoral immune response and protective efficacy of a divalent vaccine candidate consisting of rOmp25 and rL7/L12 against Brucella infection in mice.…”

Section: Discussionmentioning

confidence: 99%

“…Although recombinant subunit vaccines offer no residual virulence but these require administration of multiple boosters along with providing lower levels of protection [22]. Further, when these Brucella protective antigens were administered in combination, the induced immune responses were superior in clearing intracellular Brucella as compared to their univalent counterpart [14,15,18,[23][24][25][26][27]. Earlier studies have suggested that Omp25 and L7/L12 can serve as efficient protective antigens by inducing strong humoral and cellular immune response [17,20,28].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Simultaneous Immunization with Omp25 and L7/L12 Provides Protection against Brucellosis in Mice

et al. 2020

View full text Add to dashboard Cite

Currently used Brucella vaccines, Brucella abortus strain 19 and RB51, comprises of live attenuated Brucella strains and prevent infection in animals. However, these vaccines pose potential risks to recipient animals such as attenuation reversal and virulence in susceptible hosts on administration. In this context, recombinant subunit vaccines emerge as a safe and competent alternative in combating the disease. In this study, we formulated a divalent recombinant vaccine consisting of Omp25 and L7/L12 of B. abortus and evaluated vaccine potential individually as well as in combination. Sera obtained from divalent vaccine (Omp25+L7/L12) immunized mice group exhibited enhanced IgG titers against both components and indicated specificity upon immunoblotting reiterating its authenticity. Further, the IgG1/IgG2a ratio obtained against each antigen predicted a predominant Th2 immune response in the Omp25+L7/L12 immunized mice group. Upon infection with virulent B. abortus 544, Omp25+L7/L12 infected mice exhibited superior Log10 protection compared to individual vaccines. Consequently, this study recommends that simultaneous immunization of Omp25 and L7/L12 as a divalent vaccine complements and triggers a Th2 mediated immune response in mice competent of providing protection against brucellosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Simultaneous Immunization with Omp25 and L7/L12 Provides Protection against Brucellosis in Mice

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These fragments would support the stable structure of the fusion protein which contained four domains. The effectiveness of a vaccine significantly depends on stimulating a strong immune response containing both memory B and T cells [74]. The recombinant subunit vaccines which consist of epitopes can induce a more effective response than the immunity conferred by whole protein vaccines [75].…”

Section: Discussionmentioning

confidence: 99%

In Silico Design of a Chimeric Protein Containing Antigenic Fragments of Helicobacter Pylori; A Bioinformatic Approach

Ghasemi¹

2017

TOMICROJ

Self Cite

View full text Add to dashboard Cite

Abstract:Helicobacter pylori is a global health problem which has encouraged scientists to find new ways to diagnose, immunize and eradicate the H. pylori infection. In silico studies are a promising approach to design new chimeric antigen having the immunogenic potential of several antigens. In order to obtain such benefit in H. pylori vaccine study, a chimeric gene containing four fragments of FliD sequence (1-600 bp), UreB (327-334 bp),VacA (744-805 bp) and CagL(51-100 bp) which have a high density of B-and T-cell epitopes was designed. The secondary and tertiary structures of the chimeric protein and other properties such as stability, solubility and antigenicity were analyzed. The in silico results showed that after optimizing for the purpose of expression in Escherichia coli BL21, the solubility and antigenicity of the construct fragments were highly retained. Most regions of the chimeric protein were found to have a high antigenic propensity and surface accessibility. These results would be useful in animal model application and accounted for the development of an epitope-based vaccine against the H. pylori.

show abstract

“…The splenocytes were harvested from the immunized mice as described previously [17,20]. Lymphocyte subtype analysis was performed as described previously [21]. Briefly, splenocytes were labeled with fluorescein isothiocyanate (FITC)-anti-mouse CD4 + , allophycocyanin-cyanine 7 (APC-Cy7)-anti-mouse CD3 + , and phycoerythrin (PE)-anti-mouse CD8 + .…”

Section: Methodsmentioning

confidence: 99%

Evaluation of immunogenicity and protective efficacy of recombinant outer membrane proteins of Haemophilus parasuis serovar 5 in a murine model

Cai

Song

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Glässer’s disease is an economically important infectious disease of pigs caused by Haemophilus parasuis. Few vaccines are currently available that could provide effective cross-protection against various serovars of H. parasuis. In this study, five OMPs (OppA, TolC, HxuC, LppC, and HAPS_0926) identified by bioinformatic approaches, were cloned and expressed as recombinant proteins. Antigenicity of the purified proteins was verified through Western blotting, and primary screening for protective potential was evaluated in vivo. Recombinant TolC (rTolC), rLppC, and rHAPS_0926 proteins showing marked protection of mice against H. parasuis infection, and were further evaluated individually or in combination. Mice treated with these three OMPs produced humoral and host cell-mediated responses, with a significant rise in antigen-specific IgG titer and lymphoproliferative response in contrast with the mock-immunized group. Significant increases were noted in CD4+, CD8+ T cells, and three cytokines (IL-2, IL-4, and IFN-γ) in vaccinated animals. The antisera against candidate antigens could efficiently impede bacterial survival in whole blood bactericidal assay against H. parasuis infection. The multi-protein vaccine induced more pronounced immune responses and offered better protection than individual vaccines. Our findings indicate that these three OMPs are promising antigens for the development of multi-component subunit vaccines against Glässer's disease.

show abstract

Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection

Cited by 39 publications

References 49 publications

Simultaneous Immunization with Omp25 and L7/L12 Provides Protection against Brucellosis in Mice

Simultaneous Immunization with Omp25 and L7/L12 Provides Protection against Brucellosis in Mice

In Silico Design of a Chimeric Protein Containing Antigenic Fragments of Helicobacter Pylori; A Bioinformatic Approach

Evaluation of immunogenicity and protective efficacy of recombinant outer membrane proteins of Haemophilus parasuis serovar 5 in a murine model

Contact Info

Product

Resources

About